Jeffrey Sosman

  • Investigators find clues to melanoma treatment resistance

    Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway. Read More

    Oct 29, 2015

  • Vanderbilt University

    Bradfords’ strong support bolsters melanoma research

    When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC). Read More

    Sep 25, 2014

  • Vanderbilt University

    VICC researchers in spotlight at national cancer conference

    New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations. Read More

    Jun 19, 2014

  • Vanderbilt University

    VU study identifies new gene fusions in melanoma

    Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer. Read More

    Dec 19, 2013

  • Vanderbilt University

    Sosman to lead national melanoma research team

    Jeffrey Sosman, M.D., professor of Medicine and leader of the Vanderbilt Melanoma Program, will head one of two teams of researchers at prominent national institutions investigating acral melanoma, a skin cancer that typically forms on the hands, soles of the feet or under the fingernails. Read More

    Dec 12, 2013

  • Vanderbilt University

    Sosman named one of ‘hottest’ researchers in U.S.

    Jeffrey Sosman, M.D., professor of Medicine, Ingram Chair for Cancer Research and director of the Vanderbilt Melanoma Program, was named one of the Hottest Scientific Researchers of the last year by Thomas Reuters Science Watch. Read More

    Sep 26, 2013

  • 2013 Academic Enterprise Faculty Awards

    2013 Academic Enterprise Faculty Awards

    The 2013 Vanderbilt University Medical Center Academic Enterprise Faculty Awards, which were presented during Wednesday’s Spring Faculty meeting, included awards for Excellence in Teaching and Outstanding Contributions to Research. Award recipients were nominated by their faculty colleagues and chosen by the Academic Enterprise Faculty Awards Selection Committee. Read More

    May 23, 2013

  • Vanderbilt University

    Foundation lauds graduate student’s melanoma research

    Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation. Read More

    Mar 28, 2013

  • Combined drug therapy may delay melanoma progression

    Combined drug therapy may delay melanoma progression

    Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene. Read More

    Oct 25, 2012

  • Vanderbilt University

    Stand Up to Cancer TV broadcast airs Sept. 7

    Stand Up To Cancer (SU2C), the nonprofit organization that helps fund various Vanderbilt-Ingram Cancer Center (VICC) investigators, returns to prime time television for its third broadcast Friday, Sept. 7, at 7 p.m. The hourlong show featuring Hollywood celebrities, recording artists and sports figures will include special performances… Read More

    Aug 30, 2012

  • Vanderbilt University

    Study finds mutation in melanoma sensitive to drug

    An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. Read More

    Jul 26, 2012

  • Vanderbilt University

    New cancer drug shows promise in early testing

    An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Leora Horn, M.D. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer… Read More

    Jul 12, 2012

  • Image of pain pills (iStock Photo)

    Risk of secondary tumors from melanoma drug studied

    A new study offers clues on why melanoma patients who are treated with oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. Read More

    Mar 23, 2012

  • Vanderbilt University

    New melanoma drug nearly doubles survival in majority of patients

    Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. Read More

    Feb 23, 2012

  • Vanderbilt University

    Investigators seek clues to resistance to melanoma drug

    Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug. Read More

    Jan 26, 2012

  • Vanderbilt University

    Sosman named to ‘Dream Team’ of cancer investigators

    Jeffrey Sosman, M.D., professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA). Sosman is among the Dream Team’s principal investigators who will work closely with the… Read More

    Jan 5, 2012

  • Vanderbilt University


    Caudill (Vanderbilt) Devin Bender, a support specialist in the emergency department; Melinda Caudill, a medical technologist in the Virology Laboratory; and Katie Gentry, a child life specialist, each have received the Credo Award, given to staff and faculty who exemplify Vanderbilt University Medical Center’s standards for service and all-around… Read More

    Jan 1, 2012

  • Jeff Sosman

    Jeffrey Sosman named to melanoma research ‘Dream Team’

    Jeffrey Sosman (Vanderbilt) Jeffrey Sosman, professor of medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance. Sosman is among the Dream Team’s principal investigators who… Read More

    Dec 15, 2011